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Background: Multidrug resistance-associated protein 1 (MRP1), encoded by the ABCC1 gene, is an ATP-binding cassette
transporter mediating efflux of organic anions and xenobiotics; its overexpression leads to multidrug resistance. In this
study, 30 exons (from 31 in total) of the ABCC1 gene as well as and their flanking intron sequences were screened for
genetic variation, using the High Resolution Melting (HRM) method, for 190 healthy volunteers representing the Polish
population. Polymorphism screening is an indispensable step in personalized patient therapy. An additional targeted
SNP verification study for ten variants was performed to verify sensitivity of the scanning method.
Results: During scanning, 46 polymorphisms, including seven novel ones, were found: one in 3’ UTR, 21 in exons (11 of
them non-synonymous) and 24 in introns, including one deletion variant. These results revealed some ethnic differences
in frequency of several polymorphisms when compared to literature data for other populations. Based on linkage
disequilibrium analysis, 4 haplotype blocks were determined for 9 detected polymorphisms and 12 haplotypes were
defined. To capture the common haplotypes, haplotype-tagging single nucleotide polymorphisms were identified.
Conclusions: Targeted genotyping results correlated well with scanning results; thus, HRM is a suitable method to
study genetic variation in this model. HRM is an efficient and sensitive method for scanning and genotyping
polymorphic variants. Ethnic differences were found for frequency of some variants in the Polish population
compared to others.
Thus, this study may be useful for pharmacogenetics of drugs affected by MRP1-mediated efflux.
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The human multidrug resistance-associated protein 1
(MRP1) is a member of the ATP-binding cassette (ABC)
transporter superfamily and is encoded by the ABCC1 gene
[1]. MRP1 was first described by Cole et al. [2] who cloned
the overexpressed transporter from lung cancer cell line
H69AR. The gene is mapped to chromosome 16p13.1. Its
length is around 200.000 base pairs; the gene contains 31
exons encoding a protein of 1,531 amino acids, with
molecular weight of 190 kDa [3, 4]. The protein has 3
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terminal), TMD1 (middle) and TMD2 (C-terminal). They
contain 17 transmembrane helices (TM), 5 in TMD0 and 6
in both TMD1 and TMD2. The intracellular region of the
protein contains 2 hydrophilic nucleotide binding domains
(NBDs), NBD1 associated with TMD1 and NBD2 associ-
ated with TMD2 [5, 6]. They are both involved in binding
and hydrolyzing ATP, which is indispensable for substrate
transport. Each of NBDs contains highly conserved motifs:
Walker A motif which binds the β-phosphate of ATP and
Walker B motif that interacts with Mg2+ ions. There is also
a third, 13 amino acid sequence motif, between Walker A
and Walker B called the ABC signature [1, 7].
MRP1 is ubiquitously expressed in many human tissues
and physiological barriers like blood–brain or blood-testisis distributed under the terms of the Creative Commons Attribution 4.0
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lung, kidney, heart, testis, placenta, adrenal glands and
skeletal muscles, while lower levels of expression were
found in intestine, colon, brain, peripheral blood mono-
nuclear cells and liver [1, 3, 8]. With the exception of
brain cells, MRP1, in contrast to other ABC transporters,
is expressed at the basolateral membrane of polarized epi-
thelial cells where it plays a protective role against xenobi-
otics and their metabolites [3, 9].
Many drugs are good substrates for MRP1, so its over-
expression leads to multidrug resistance (MDR), especially
during cancer chemotherapy. This effect can be observed
in many types of cancer cells including solid tumors (lung
cancer, breast cancer, gastric and colon carcinomas, mel-
anoma, prostate cancer, neuroblastoma) as well as in vari-
ous types of leukemias [3, 9]. MRP1-overexpressing cells
are capable of transporting a large group of substrates, in-
cluding anticancer drugs like folate-based antimetabolites,
anthracyclines, Vinca alkaloids, antiandrogens and even
some inorganic anions such as arsenite and arsenate.
MRP1 is also an active transporter of a broad range of en-
dogenous compounds including glutathione (GSH), glu-
curonate and sulfate-conjugates of organic anions, such as
inflammatory mediator leukotriene C4 or estradiol-17-β-
D-glucuronide (E217βG). Therefore, MRP1 plays a crucial
role in efflux of organic anions, anionic drugs, xenobiotic
conjugates and additionally in the maintenance of redox
balance by participation in cellular response to oxidative
stress [3, 7, 9–11].
A large number of single nucleotide polymorphisms
(SNPs) in ABCC1 gene were detected so far in studies of
various populations, especially Asian and Caucasian. Saito
et al. [12] reported 779 genetic variations in eight ABC
genes in Japanese population, 95 among them concerning
ABCC1. Subsequently, Fukushima-Uesaka et al. [13],
screening ABCC1 in the same population, identified 86
genetic variations including 31 novel ones. Similar screen-
ing of Chinese population revealed 32 SNPs [14].
Leschziner et al. [15] screened five ABC transporter genes
in Caucasian individuals and detected 221 variants, includ-
ing 61 for ABCC1, among them 22 novel for this gene.
They identified also large blocks of high linkage disequilib-
rium and low haplotype diversity across all the genes in
the examined population. Comparative study including
polymorphisms from four different populations: Chinese,
Malay, Indian and Caucasian showed that apart from
population-specific SNPs, only 6 of 71 detected SNPs al-
tered amino acid sequence, so ABCC1 is considered to be
a highly conserved gene [16]. Majority of previously re-
ported genetic variations were found in intron sequences.
However, there is evidence in literature that some SNPs
change protein functioning and effectiveness of cancer
chemotherapy. Such cases were reported for neuroblast-
oma [17], breast cancer [18], ovarian cancer [19] and otherserious diseases like: chronic obstructive pulmonary dis-
ease (COPD) [20, 21] cystic fibrosis [22] and major de-
pression [23].
Previously mentioned studies have shown importance of
ABCC1 polymorphisms and its genetic variation. These
data can have great relevance for pharmacogenetics in per-
sonalized patient therapy. Based on the data described
above for several populations, there exist ethnic differ-
ences in the frequency of ABCC1 polymorphic variants.
Some of them are so strongly linked to each other that
they are always inherited together, forming haplotypes.
Haplotype is a combination of polymorphic variants inher-
ited on the same chromosome and sometimes has stron-
ger clinical relevance for drug response or adverse events
than a single polymorphism [24]. Moreover, there is a
large haplotype diversity across different populations [25].
Therefore, prior comprehensive analysis of the whole gene
is required in the specific population before application of
genetic variation data in pharmacotherapy.
Our previous studies performed during the project
TESTOPLEK in which we have examined genetic vari-
ation of multidrug transporter genes in the Polish
population indicated that ABCC1 polymorphisms were
present at significant level in a sample of Polish individ-
uals. However, various SNPs in the ABCC1 gene dif-
fered significantly in their frequency in tested DNA
samples [26]. This prompted us to verify the whole cod-
ing sequence of ABCC1 gene. We conducted high
throughput analysis and screened 30 exons (from 31 in
total) of ABCC1 gene for polymorphism variants in the
Polish population (which is exclusively Caucasians).
This is the first study of genetic variation of ABCC1
gene in the Polish population.
Methods
Materials and genomic DNA samples
Human genomic DNA samples were derived from an-
onymous Polish unrelated volunteers who declared to be
healthy. Samples were randomly selected from the “nor-
mal Polish population” genetic collection at the Biobank
Lab, Department of Molecular Biophysics, University of
Lodz. Genetic material for this collection was sampled in
2011 – 2012 within the EU-funded TESTOPLEK project.
All subjects gave their written informed consent to partici-
pate in the study. This study was approved by the relevant
regional ethical committee (Research Bioethics Commis-
sion, University of Lodz - Decision no. 8/KBBN-UŁ/II/
2014 and Statement of the Research Bioethics Commis-
sion, University of Lodz from 17th of June, 2010) and all
procedures were performed in accordance with the Dec-
laration of Helsinki.
Saliva was collected into Oragene OG-500 DNA collec-
tion/storage receptacles (DNA Genotek, Kanata, Canada)
and genomic DNA was subsequently isolated by the
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(Roche, Basel, Switzerland) with final concentration nor-
malized to 200 pg/μl [27]. A total of 190 samples were en-
rolled in the scanning study and other 380 in genotyping.
Screening of ABCC1 by High Resolution Melting (HRM)
Method
Investigation of ABCC1 genetic variation was conducted
using High Resolution Melting method. The method is
based on precise measurements of DNA melting profile.
The dsDNA melting temperature depends on length and
nucleotide composition of the PCR product. Even a single
base variation generates a different melting curve, and
many variants can be detected in this way. The list of
primers used for HRM scanning of all the areas is pre-
sented in Table 1. The single reaction mixture (10 μl) was
prepared using Janus® Automated Workstation (Perkin
Elmer Inc., Waltham, USA) and composed of GoTaq®
Colorless Master Mix (2×) (Promega, Madison, USA), LC
Green Plus® dye (10x) (BioFire Defense Inc., Salt Lake
City, USA), 0.5 μl of 10 μM primers mixture, 3 μl DNA,
and filled up to the final volume with water. Reaction was
performed on 384-micro well plates using CFX384™ real-
time PCR system (Bio-Rad Laboratories Inc., Hercules,
USA) on duplicate samples. The reaction conditions were
as follows: initial denaturation at 95 °C for 3 min, 50 amp-
lification cycles of denaturation at 95 °C for 30 s and an-
nealing at specific temperature depending on the primers
used, for 30 s. The plate was read after each cycle. Directly
afterwards, melting curve was determined, the plate being
incubated at 90 °C for 60 s, 40 °C for 60 s and from 65 °C
to 95 °C with an increment of 0.2 °C for 10 s with plate
reading. The obtained data were analysed with the Bio-
Rad Precision Melt Analysis Software, version 1.2 (Bio-
Rad Laboratories Inc., Hercules, USA). Based on HRM
melting curve analyse, confirmation of genetic variation
for every melting cluster was obtained by direct sequen-
cing method for several samples selected from each clus-
ter (or all samples from clusters with less than 4 samples).
Study workflow design for all described methods is pre-
sented in Fig. 1.
HRM genotyping
Independently of the scanning study, we performed an
additional genotyping study. We focused on highly
polymorphic regions of the ABCC1 gene existing in da-
tabases, often examined in recent publications. We also
tested some interesting variants observed in literature
that may have clinical significance. The selection pro-
vided us with 17 SNPs to check. To identify common
genetic variation of selected SNPs in the ABCC1 gene,
we used the HRM analysis method according to condi-
tions described above. Sequences of primers used for
genotyping are described in Table 1. Based on HRMmelting curve analysis, confirmation of genetic variation
for every melting cluster was obtained by direct sequen-
cing method for several samples selected from each
cluster (or all samples from clusters less than 3 sam-
ples). We used the data obtained from genotyping to
compare them with HRM scanning results (comparison
of minor allele frequencies - MAFs) and thereby to val-
idate the accuracy of the screening method.
DNA sequencing
For sequencing, selected samples were prepared by
PCR. Reaction mixture filled with water to a final vol-
ume of 50 μl per sample was composed using GoTaq®
Green Master Mix (2×) (Promega, Madison, USA), 5 μl
of 10 μM primers mix and 5 μl DNA. Reaction condi-
tions were as follows: an initial denaturation at 95 °C
for 3 min, 45 amplification cycles of denaturation at
95 °C for 30 s, annealing at specific temperature de-
pending on the primers used for 30 s and extension at
72 °C for 45 s, followed by final extension at 72 °C for
5 min (list of primers for exon sequencing is shown in
Table 1). Afterwards, PCR products were purified using
NucleoSpin® Gel and PCR Clean-up kit (Macherey-
Nagel GmbH & Co. KG, Düren, Germany). DNA concen-
tration and size of PCR product was determined by
agarose electrophoresis of 2 μl of each sample. Based on
the intensity of bands the samples were diluted from 5 to
50 times and applied for sequencing reaction using BigDye
Terminator V3.1 (Applied Biosystems, USA) according to
the manufacturer's protocol. The PCR-sequencing product
was purified using BigDye X-Terminator kit following the
manufacturer's protocol (Applied Biosystems, USA). Fur-
ther, 30 μl of each purified sample was applied to 96 wells
of titration plates and analyzed in 3500 Genetic Analyzer
(Applied Biosystems, USA).
Polymorphism detection
The ABCC1 genomic DNA sequence (NG_028268.1) was
obtained from GenBank (http://www.ncbi.nlm.nih.gov)
and used as a reference sequence during analysis of se-
quencing results by CodonCode Aligner software (Codon-
Code Corporation, Centerville, USA). Sequencing results
of selected samples were compared with respective HRM
clusters. Based on this, genotype for each melting cluster
was established and genetic variation for each sample was
verified.
Availability of supporting data
For each of the polymorphisms detected in this study in
ABCC1 gene, the following parameters were assigned:
dbSNP IDs (rs numbers) (http://www.ncbi.nlm.nih.gov/
SNP/), nucleotide position within or relative to the coding
sequence based on the NM_004996.3, and amino acid
position in the protein for SNPs in the coding sequence
Table 1 Pairs of primers used for HRM screening, sequencing and genotyping ABCC1
Exon Number of scanned bp upstream
from the exon (without primer)
Forward primer (5’→ 3’) Reverse primer (5’→ 3’) Number of scanned bp
downstream from the
exon (without primer)
Size (bp) including primers
Scanning 1 104* CAGCGCTAGCGCCAGCAG CCCGGTGCTTTCCCTCCC 49 234
2 31 GTCCTCTGGGGTGTGTCCT TCTGAATGTAGCCTCGGTCA 201
GCTTTCAGAACACGGTCCTC TTATCACCAACCACCACTCC 52 203
3 20 GGGCGGTCTGTTGTAGGATA CCACTGAGCCCAGCAGAT 31 215
4 129 AAGCTGAGGCAGGAGAATCA AAGGTAGCAAGCAGCTGAGG 163
AGCCTGGGTGACAAGAGTGA TGGATCTCAGGATGGCTAGG 189
ATGCTCACTTTCTGGCTGGT GGCAACGCATGACTTCTACA 72 170
5 27 CAGCCCCAGAATGTGATCTT CACACACACGCACACACACT 19 212
6 20 TTTCCCTCTTCCTCCCAAAC AGCTGAGCATGTTCATTCGTT 59 182
7 33 CCCTCCTCCTGTCATTGACTC GAGTGGAAAGGAGGTGACCA 240
GGAACAAGTCGTGCCTGTTT ATCTTGCCCAGAACCACAAA 104 184
8 74 TTCCCTGAAGGGTGACATTC AGGGGTTCCACTCCTTCTGT 219
GGAGGCTTTGATCGTCAAGT AAAGCCAAGGAGGGAAAATG 29 199
9 14 AGTCATTCCAGGCCCTCTCT TGACGAAGCAGATGTGGAAG 165
TACACCGTGCTGCTGTTTGT CAGGAGGGGATGTGGAAGT 33 175
10 27 TCTTCAGCTGCCACACTCAC GCCACAGGAGGTAGAGAGCA 207
TCTGTGGACGCTCAGAGGTT CTGCCCACACGTAGAAGTCC 38 157
11 21 TCTTCTGTCTGGTGAGTGATGAA TGGACTAAAATCCTCATGGAGAG 49 209
12 41 GTTGAGTGATGGGCTGATCC GGCAGACTTCTTCAGCACCT 217
GCATTCAAGGACAAGGTGCT CCTGGGCAACATAGTGACCT 75 206
13 62 GTCTCCAGGGCCTGTCACT ACCGGAGGATGTTGAACAAG 184
CCAGACAGCCTTCGTGTCTT GCTTTCGTGGCCTAGAACC 42 149
14 49 TTAACCTTGGTTGGTTTTGC CAAGTAGGGAGGACCCAGTG 51 228
15 41 GTTCTGTGCATGTGGAGTCG GGCTCTCTCCACACCATCAC 22 179
16 73 TTCTCTACTTGGGGTAAATTGAGG CTGAGAGCAGGGACGACTTT 177
ATCCCCGAAGGTGCTTTG GCTTTTCCTCAGACCACCAG 37 171
17 12 CTGTCTCACCTCGTTCTCCA CTGACCTTCTCGCCAATCTC 214
CTCCCAGACCTGGAAATCCT CAGCCCACTGAGATTGTGAG 60 134
18 20 ATTTCCCAGGAAACCCACTC GGCCAATCACATTTTCAAAGA 185
CTTCGATGATCCCCTCTCAG CCTAAAGGGGACACGTTCTG 55 166













Table 1 Pairs of primers used for HRM screening, sequencing and genotyping ABCC1 (Continued)
GCCAAGCTAGGCAGTCTCAC GGCAAGTAGCTCATGCTGTG 99
TCTGAGATGGGCTCCTACCA CAACCTCAAAGAGGCCAATG 56 182
20 48 TTGTTGCCCTTGGTTTTAGC CTCCTCTTGTCCTCCCACTG 44 223
21 20 GCATCTGTACGGTTGACACC TGGGCGCTCTATAAACTCCA 32 228
22 25 GGTGCGTGCATGTGCTAAG ATGGGGTCATCAGTCCAGAG 184
GGCTTCCAACTATTGGCTCA CAAAACGCTGAGGACTCTAAGG 72 204
23 21 CCCTCTCTGCATTGTGGAGT GTCCACTGTGTCCAGCTCCT 214
ATGAGCTTCTTTGAGCGGAC GGCTTGTCCCGAACACTAAG 14 244
24 22 GAGGGAACCTTCATCAACTCC TCTGGTTCTCGTCCACCTTC 212
CCCATTTCAACGAGACCTTG GGAAAAGATCGAGGCAAAGA 55 208
25 26 AGAGCTGACTCCATGCCTGT GGCTCCCCCATTAACAGACT 32 225
26 24 CGCCCGCTTACTCTAGAAAT CCAAAGACCAAGAGGTCCAG 18 184
27 45 GGGGAGTCACAGCTTTACCA GGGAATGGGTGAGGGAAT 18 248
28 6 ACACCTGGGCCCTTCTGTC TGATCTCTCCTTCGGCAGAC 113
CTGGGCTTATTTCGGATCAA CAGTGCAATCATAGGGCTTG 40 174
29 55 AGTCCTTAGGTCGCCTCCAT CCTTCTGCACATTCATGGTC 227
CCCACCTGAAGGACTTCGT CAAACACCCCTACCGAGATG 47 143
30 74 GTGTCTCCTTTCGCTTCTCC ATGGTGGACTGGATGAGGTC 217
CCTGCTGAGGAAGACGAAGA AGGCAAACTCCCAAAGCCTA 25 204
31 15 CCCTTCCCCTCATGTCTGTA ATAGGCCCTGCAGTTCTGAC 21** 185
Sequencing 1 - - -
2 TCTCGAACTCCCAGCCTAAA TAAGCGGCAGAGCAAAGATT 749
3 GAGCATGGTGACCAGACAAA CTCCTGACCTCAGGTGATCC 638
4 GTGGTGAAACCCCGTCTTTA CCTTGGAGCAACACAGACAA 604
5 CCCGAGTAGCTGGGATTACA ACCATGCCAAGTGAGAAACC 606
6 GGGTTGTTGTGGGGATAGAA AAGCAAAAGCAGTCCAGCAT 622
7 CTGCATGACCCAACAGAATG CAAACTCCCGACCAAGTGAT 651
8 CTTTGACTCTGCCTTCCCTG TAGGGGAGCCTAGTGGGTTT 691
9 AGCAATTAGTGCACAACCCC AAGACATCTACACGCCCACC 613
10 ACAGCCTGGAAGCGTAGAAA AACTGCCAGGGAGCTCTACA 664
11 GAGCGTGGACCTGCTTATTC CACCGGCCTACAAGGTCTAA 608
12 GATGTTGAGTGATGGGCTGA CCTGGGCAACATAGTGACCT 363













Table 1 Pairs of primers used for HRM screening, sequencing and genotyping ABCC1 (Continued)
14 CTGGGGAAACCCTTGAAAGT CCAAGGGAAAGAAATGCAAG 263
15 CCCAAGATGATCGTCCAGAT TACGCAAGCCAAGAATCTCC 632
16 TCTCCTTTCAGACCTTGCGT CCTGCCTTCTAGGACAGCAC 676
17 ACTCTTTGGAAGCAGGGGTT AGTGAGACCTGAGCCACACC 693
18 CTCAAGCCATCTTCCCACTC GAAGCCAGCCCTGTGACTTA 717
19 CATGTCCCACCTTCAGACCT CCAGCTTAACTCCGTGCTTC 748
20 CTGCACAGTTGCAAAGCACT GCCAAGAGACCTGAGCAAAG 620
21 CCGTCTCTTATGCCATGGTT GGTTCAAATCCCAGTTCTGC 461
22 GCATGTGCTAAGCTGCCTTAT TGTAAAATGGGCACACTGGA 485
23 CTCAAGTGATCCACCCACCT TGCTTCAAAAGCACCACACT 617
24 GAGGTTAGCACTTTGCAGCC ATGATTCATCTGTCCTCCGC 791
25 AAGGCAAGCTTCAGATTCCA AAAGCATTCCCCTCGTACCT 674
26 AAATGCCACGTGACTCTTCC CCTGGTGAGGTATCCAGCTC 242
27 AGGGGACAGAGGGACACAG AAATCTGTGGGGCTCATTTG 618
28 TCATGATGGGAAACTCACCA GAACGATGAAGTAGGGCCAA 669
29 AGACAGGGTGTTGCCATGTT TCAACTGAATGGAGCTGGTG 689
30 GGTGTGAGCTGCTGTTTTGA AAGAGAGGATCCACCCACTG 556
31 CCATGATTGATGTGGGGTAG AAGCACCAGGAAACCACTTG 640
Genotyping SNP Forward primer (5’→ 3’) Reverse primer (5’→ 3’) Size (bp) including primers
c.128G > C TCAGAACACGGTCCTCG ACAGGCCCAGAGGTAAAA 49
c.616-7942A > G AGCAACAGGGCAAACAAATC GACGGAGCCTAAATGTCCAG 76
c.816G > A CTTGTGTTCCAGGCAGC GCAGGATCCTTGGAGGAGTA 51
c.825 T > C
c.1057G > A GCTCCTTTGCAGGTTGCTCATC GGGGCCTTCGTGTCATTCA 48
c.1062 T > C GGTTGCTCATCAAGTTCGTGA GTCTGGGGCCTTCGTGTC 41
c.1218 + 8A > G CATGAGGATCAAGACCGCTG GTGGAAGTCGGGCCACAT 84
c.1299G > T CCAGAAAATCCTCCACGGT GTACGTGGCCAAGTCCATGA 80
c.1684 T > C GTTCTGCTTGCAGGAGGCC TTCAGGGGAAACCGGAGGAT 125
c.1704C > T
c.2012G > T TCACCTTCTCCATCCCCG CACTTTGTCCATCTCAGCCA 104













Table 1 Pairs of primers used for HRM screening, sequencing and genotyping ABCC1 (Continued)
c.2581G > A CAGGAGCTGCTGGCTCG TCTGTGCTGGCATAGGTACG 62
c.2965G > A TCCTTTTCATGTGTAACCATGTG CAATAGTTGGAAGCCAGCG 46
c.3140G > C CTACTCCATGGCCGTGTCC AGGATGCTGTGCAGCAGGT 75
c.3436G > A GAGGTTCTACGTGGCTTCC GAATAGACCGGGGAGCG 69
c.4002G > A GACAAGTCCGGATGCCAG CGAAATAAGCCCAGGGTC 112
c.4009A > G AGCTGGGAAGTCGTCCCT TGATCTCTCCTTCGGCAG 65













Fig. 1 Study flow chart
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were obtained from GenBank (http://www.ncbi.nlm.nih.
gov) and were used in this paper as the nomenclature of
variants.
The obtained data as supporting materials are pre-
sented in details in Additional files 1, 2, 3 and 4.Prediction of impact of SNPs upon protein functionality
Using PolyPhen-2 v2.2.2r398 tool (http://genetics.bwh.
harvard.edu/pph2/), we performed automatic prediction
of effects of missense SNPs and amino acid substitutions
for protein functionality and structure. PolyPhen-2 uses
damaging alleles datasets, like HumDiv or HumVar, to
calculate naïve Bayes posterior probability and to classify
a mutation deleterious effect as benign, possibly damaging
or probably damaging. This ternary classification depends
on thresholds of false positive rate (FPR) denoting the
chance that mutation would be falsely qualified as deleteri-
ous. For HumDiv-trained model, the thresholds are 5 %and 10 % FPR while for HumVar-trained model they are
10 % and 20 % FPR, respectively [28].
Linkage disequilibrium and haplotype blocks analysis
The observed genotype distribution was determined for
all the detected polymorphisms by performing the
Hardy-Weinberg equilibrium (HWE) exact test assum-
ing consistency for P-value higher than 0.001. Linkage
disequilibrium (LD) and haplotype block analysis was
performed by Haploview 4.2 software (http://www.
broad.mit.edu/mpg/haploview/). The LD analysis was
made using |D’| and r2 parameters for each variation pair.
|D’| coefficient was preferentially used to model recom-
bination rates in examined population, and r2 parameter
to model association power [29, 30].
Studying haplotypes in the human genome requires
definition of the location of haplotype blocks, which are
regions with little evidence for historical recombination
and within which only a few common haplotypes are ob-
served [31]. To determine haplotype blocks in ABCC1
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previously by Gabriel et al. [31] based on confidence
bounds on D’. For pairs of SNPs being in strong linkage,
95 % upper confidence bound D’ was higher than 0.98
and the lower bound was above 0.7 while for pairs of
SNPs with strong evidences of historical recombination
upper bound on D’ is lower than 0.9. According to this
model, polymorphisms with MAF [22] lower than 0.05
were excluded during the creation of blocks and 16
polymorphic variants with higher MAF were included.
Haplotypes with frequency lower than 1 % were grouped
as “others”.Results
ABCC1 genetic variation detected in this study
We screened coding regions and exon/intron boundaries
as the most important gene areas (Additional file 1). To
assure optimal detection level, the maximal length of
tested PCR product was never longer than 250 and 125
base pairs for scanning and genotyping, respectively. For
scanning, most of exons had to be divided into separate
scanned areas, which provided 51 fragments for analysis.
We performed complete polymorphism screening in 30
exons in total. We were unable to scan exon 1 because
of problems with amplification during PCR, caused by
extremely GC-rich sequence region.
In the scanning study on 190 Polish volunteers, we
found 46 different SNPs in the scanned areas, and seven
of them being novel and not reported yet (Table 2). 21
SNPs were located in exons and 11 of them change amino
acid sequence as non-synonymous variants, including one
novel polymorphic variant detected in this study:
c.596C > T (p.Ser199Leu) with MAF = 0.003. Among
all detected non-synonymous variants, only one,
c.2012G > T (p.Gly671Val), occurred as a homozygote
with estimated MAF = 0.077. The rest of SNPs found
homozygously in exons were synonymous variants which
resided at: c.825 T > C (p.Val275=), c.1062 T > C
(p.Asn354=), c.1684 T > C (p.Leu562=), c.1704C > T
(p.Tyr568=) and c.4002G > A (p.Ser1334=) with MAF
values equal to 0.309, 0.332, 0.130. 0.088 and 0.277, re-
spectively. Apart from polymorphisms in coding regions,
23 SNPs were located in introns and a last one (c.*3C > G)
in the 3’ UTR. Furthermore, one intron deletion variant
c.2461-39_2461-38delAT was found during the scanning.
Two polymorphic variants located in introns, c.2871 +
26C > T and c.3079 + 10G >A, occurred only as non-
reference homozygotes in all subjects.
We used the data from genotyping study to validate
our scanning results and compare accuracy of HRM
methods (Additional file 2). For genotyping, we tested
a subset of 17 SNPs, selected according to the litera-
ture or detected during scanning. Seven of them havenot been found during scanning in examined samples
and also did not show any genetic variation by genotyp-
ing method. Genotype validation by sequencing was per-
formed for all of examined SNPs (Table 3). We calculated
MAFs to enable us to assess the accuracy of scanning
method compared to genotyping. Results obtained for
eight of SNPs were quite similar and the differences were
not statistically significant (Table 3). We found statistically
significant difference in MAF values obtained in the both
our studies for only two loci – c.1062 T > C (p.Asn354+)
and c.2012G > T (p.Gly671Val).
All the amino acids altered by non-synonymous vari-
ants were located in cytoplasmic domains of the pro-
tein. Variants c.596C > T (p.Ser199Leu) and c.814C > T
(p.Pro272Ser) were located in the third intracellular
loop (between TM5 and TM6), variant c.1299G > T
(p.Arg433Ser) in the fourth intracellular loop, variant
c.3196C > T (p.Arg1066Trp) in the seventh intracellular
loop (between TM7 and TM8). Additional four variants
located in the loop containing NBD1 alter amino acids
sequence: c.1898G >A (p.Arg633Gln) and c.2012G > T
(p.Gly671Val) are located 44 and 6 amino acids upstream
of the Walker A motif, respectively, while c.2168G >A
(p.Arg723Gln) and c.2876A >G (p.Lys959Arg) are located
37 amino acids downstream of this motif, respectively.
Similarly, three variants changing amino acids in the
loop containing NBD2 were detected: c.3886C > T
(p.Arg1296Trp) and c.3901C > T (p.Arg1301Cys) are lo-
cated 30 and 25 amino acids upstream of the Walker A
motif, respectively, while c.4093G > A (p.Asp1365Asn)
is located 30 amino acids downstream of the motif. De-
tected variant c.4002G > A (p.Ser1334=) occurred in the
last position of Walker A motif in NBD2, however it
does not change the amino acid sequence.
Analysis of all the non-synonymous variants detected
in this study by the PolyPhen-2 tool (data in Additional
file 3) showed for HumDiv-trained model that five of
them: c.814C > T (p.Pro272Ser), c.1898G >A (p.Arg633
Gln), c.2168G >A (p.Arg723Gln), c.2876A >G (p.Lys
959Arg), the novel one c.4093G >A (p.Asp1365Asn),
probably have benign influence on the functioning of
the protein. For one polymorphism, c.3196C > T
(p.Arg1066Trp) a possibly damaging effect on protein
activity was expected. The novel variant c.596C > T
(p.Ser199Leu) was estimated as a probably damaging
substitution, likewise as four others: c.1299G >T (Arg433
Ser), c.2012G >T (p.Gly671Val), c.3886C >T (p.Arg
1296Trp) and c.3901C >T (p.Arg1301Cys). On the other
hand, analysis for HumVar-trained model indicated that
three polymorphisms: c.1299G >T (Arg433Ser), c.2012G >
T (p.Gly671Val), c.3901C >T (p.Arg1301Cys), lead to
probably damaging substitutions and two others, c.596C >
T (p.Ser199Leu) and c.3886C >T (p.Arg1296Cys), are
possibly damaging variants.
Table 2 Summary of ABCC1 variants detected during scanning by HRM
Exon scanned
by HRM









2 rs8187843 c.225 + 26G > A Intron 164 25 0 1 (A) 0.066
4 rs587783373* c.352-79G > A Intron 185 1 0 1 (A) 0.003
4 rs4148337 c.352-66 T > C Intron 15 80 91 0.727 (T) 0.296
5 rs483352860* c.596C > T p.Ser199Leu 186 1 0 1 (T) 0.003
6 rs8187846 c.677 + 17C > T Intron 188 1 0 1 (T) 0.003
7 rs483352864* c.809 + 16C > T Intron 188 1 0 1 (T) 0.003
7 rs45609533 c.809 + 31G > T Intron 183 5 0 1 (T) 0.013
7 rs903880 c.809 + 54C > A Intron 112 65 11 0.684 (A) 0.231
7 rs246232 c.809 + 64C > G Intron 84 90 14 0.174 (G) 0.314
8 rs546943313 c.810-73C > T Intron 187 1 0 1 (T) 0.003
8 rs200194736 c.814C > T p.Pro272Ser 187 1 0 1 (T) 0.003
8 rs2230669 c.816G > A p.Pro272= 172 16 0 1 (A) 0.043
8 rs246221 c.825 T > C p.Val275= 84 92 12 0.059 (C) 0.309
8 rs587783372* c.855G > A p.Pro285= 187 1 0 1 (A) 0.003
9 rs35587 c.1062 T > C p.Asn354= 78 91 16 0.185 (C) 0.332
9 rs35588 c.1218 + 8A > G Intron 82 91 16 0.245 (G) 0.327
9 rs483352877* c.1218 + 9C > T Intron 188 1 0 1 (T) 0.003
10 rs60782127 c.1299G > T p.Arg433Ser 186 2 0 1 (T) 0.005
12 rs17265551 c.1677 + 56C > T Intron 162 27 0 0.604 (T) 0.072
13 rs35604 c.1678-37G > A Intron 2 45 142 0.745 (G) 0.130
13 rs483352863* c.1678-34G > A Intron 188 1 0 1 (A) 0.003
13 rs35605 c.1684 T > C p.Leu562= 2 45 142 0.745 (T) 0.130
13 rs8187858 c.1704C > T p.Tyr568= 157 31 1 1 (T) 0.088
14 rs112282109 c.1898G > A p.Arg633Gln 187 1 0 1 (A) 0.003
16 rs8187863 c.2001C > T p.Ser667= 187 1 0 1 (T) 0.003
16 rs45511401 c.2012G > T p.Gly671Val 161 25 2 0.296 (T) 0.077
17 rs4148356 c.2168G > A p.Arg723Gln 181 9 0 1 (A) 0.024
19 rs45607032 c.2461-39_2461-38delAT Intron 179 9 0 1 (delAT) 0.024
19 rs2074087 c.2461-30C > G Intron 0 44 144 0.083 (C) 0.117
19 rs45492500 c.2461-27G > A Intron 172 14 2 0.056 (A) 0.048
21 rs11075296 c.2871 + 26C > T Intron 0 0 189 1 -
22 rs768191257 c.2876A > G p.Lys959Arg 187 1 0 1 (G) 0.003
22 rs3851716 c.3079 + 10G > A Intron 0 0 188 1 -
22 rs34794353 c.3079 + 24C > T Intron 187 1 0 1 (T) 0.003
22 rs3887893 c.3079 + 62 T > C Intron 67 96 25 0.358 (C) 0.388
23 rs191017838 c.3171G > A p.Leu1057= 187 2 0 1 (A) 0.005
23 rs199773531 c.3196C > T p.Arg1066Trp 188 1 0 1 (T) 0.003
25 rs41278168 c.3591-5C > T Intron 187 1 0 1 (T) 0.003
27 rs200922662 c.3886C > T p.Arg1296Trp 187 1 0 1 (T) 0.003
27 rs201533167 c.3901C > T p.Arg1301Cys 187 1 0 1 (T) 0.003
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Table 2 Summary of ABCC1 variants detected during scanning by HRM (Continued)
28 rs2230671 c.4002G > A p.Ser1334= 102 68 18 0.202 (A) 0.277
28 rs188980645 c.4093G > A p.Asp1365Asn 187 1 0 1 (A) 0.003
29 rs212087 c.4126-45G > A Intron 62 85 42 0.239 (A) 0.447
30 rs212088 c.4487 + 18G > A Intron 136 47 5 0.775 (A) 0.148
31 rs587783374* c.4551G > A p.Gln1517= 186 1 0 1 (A) 0.003
31 rs373453875 c.*3C > G 3’ UTR 186 1 0 1 (G) 0.003
*Novel polymorphic variants detected in this study. aNumber of genotypes detected during this study, R – reference allele, V – variant allele. bTotal number of
examined samples was 190, however during scanning single samples were excluded because of accidental problems with amplification during PCR and hence,
total number of genotypes is not equal precisely 190. cP-value is consistent with Hardy-Weinberg equilibrium if P > 0.001. dMinor allele shown in brackets with its
frequency. Bold variants signifies the ones which were validated by genotyping results
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Based on full genotype sets of 44 polymorphic variants
confirmed by Hardy-Weinberg equilibrium exact test
(Table 2), linkage disequilibrium analysis using r2 and
|D’| statistics was performed (Additional file 4). Accord-
ingly to the r2 parameter, perfect linkage (r2 = 1) was de-
tected between the new variant c.809 + 16C > T and
c.3196C > T, between c.1678-37G > A and c.1684 T > C,
between c.2168G > A and c.2461-39_2461-38delAT. Al-
most perfect linkage was observed between c.1062 T > C
and c.1218 + 8A > G (r2 = 0.928), between c.825 T > C
(p.Val275=) and c.1062 T > C (p.Asn354=) (r2 = 0.822)
and between c.825 T > C (p.Val275=) and c.1218 + 8A >G
(r2 = 0.894). Apart from perfect linkage between variantsTable 3 Summary of ABCC1 selected SNPs genotyping by HRM and







rs41395947 c.128G > C p.Cys43Se 380 0
rs2230669 c.816G > A p.Pro272= 362 18
rs246221 c.825 T > C p.Val275 197 160
rs8187852 c.1057G > A p.Val353Met 379 0
rs35587 c.1062 T > C p.Asn354= 204 142
rs35588 c.1218 + 8A > G Intron 190 160
rs60782127 c.1299G > T p.Arg433Ser 373 6
rs35605 c.1684 T > C p.Leu562= 13 105
rs8187858 c.1704C > T p.Tyr568= 325 55
rs45511401 c.2012G > T p.Gly671Val 346 28
rs4148356 c.2168G > A p.Arg723Gln 360 19
rs45517537 c.2581G > A p.Ala861Thr 380 0
rs35529209 c.2965G > A p.Ala989Thr 378 0
rs13337489 c.3140G > C p.Cys1047Ser 380 0
rs28706727 c.3436G > A p.Val1146Ile 380 0
rs2230671 c.4002G > A p.Ser1334= 204 140
rs28364006 c.4009A > G p.Thr1337Ala 380 0
aNumber of genotypes detected during this study, R – reference allele, V – var
P > 0.001. cMinor allele shown in brackets with its frequency. dP-value of Chi-sq
if P > 0.05c.1678-37G > A and c.1684 T > C, they were both strongly
linked (r2 = 0.705) with c.2461-30C >G. Other linkages
(r2 = 0.624 and r2 = 0.658, respectively) were found be-
tween c.225 + 26G > A and c.816G > A, and between
c.809 + 54C > A and c.809 + 64C >G.
For the |D’| values, perfect linkage (|D’| = 1) was ob-
served for the great majority of variants pairs (760 for 946).
Strong linkage (1 > |D’| ≥ 0.8) was detected for other 17
pairs. Small areas of low |D’| values, and hence weak or
lacking of linkage, were defined between polymorphisms
from group: c.225 + 26G > A, c.352-66 T > C, c.809 +
31G > T, c.809 + 54C > A, c.809 + 64C > G, c.816G > A,
c.825 T >C, c.1062 T >C, c.1218 + 8A >G, c.1677 + 56C >










0 1 – – –
0 1 (A) 0.024 (A) 0.043 0.079
23 0.243 (C) 0.271 (C) 0.309 0.187
0 1 – – –
33 0.247 (C) 0.274 (C) 0.332 0.044
30 0.709 (G) 0.289 (G) 0.325 0.214
0 1 (T) 0.008 (T) 0.005 0.623
262 0.588 (T) 0.172 (T) 0.130 0.063
0 0.242 (T) 0.072 (T) 0.087 0.374
3 0.007 (T) 0.045 (T) 0.077 0.038
0 1 (A) 0.025 (A) 0.024 0.888
0 1 – – –
0 1 – – –
0 1 – – –
0 1 – – –
32 0.296 (A) 0.271 (A) 0.277 0.850
0 1 – – –
iant allele. bP-value is consistent with Hardy-Weinberg equilibrium if
uare test with Yates’ correction, no significant difference between MAFs
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38delAT, c.2461-30C > G, c.2461-27G > A, c.3079 +
62 T > C, c.4002G > A, c.4126-45G >A, c.4487 + 18G >A.
Haplotype block analysis
Based on the model of Gabriel et al. [31] a total of 12
common haplotypes were identified and their frequencies
were defined in four blocks (Table 4). In block 1, variants
c.809 + 54C > A and c.809 + 64C >G were included, and
the most frequent haplotype in this block was that con-
taining major alleles (frequency: 0.686), the next most fre-
quent one was the haplotype with both minor alleles
(frequency: 0.231). Block 2 spanned SNPs c.825 T > C
(p.Val275=), c.1062 T > C (p.Asn354=) and c.1218 + 8A >
G at a distance of 1 kb, with the most frequent haplotype
containing all major alleles (frequency: 0.659), subse-
quently the haplotype with all minor alleles (frequency:
0.300), two other ones had low frequency (set alleles TCG:
0.021 and set alleles TCA: 0.011). Block 3 had two haplo-
types composed of SNPs c.1678-37G > A and c.1684 T > C
(p.Leu562=). The first haplotype was the set with major al-
leles (frequency: 0.870) and the second one the set with
minor alleles (frequency: 0.130). Block 4 was created of
SNPs c.4126-45G >A and c.4487 + 18G >A at a distance
of around 2 kb. The most frequent haplotype was that of
alleles combination AG (frequency: 0.447), the next ones
with major alleles (frequency: 0.405) and allele combin-
ation GA (frequency: 0.148). The frequency of recombin-
ation was also calculated between blocks as a value of
multiallelic D’ coefficient, and equaled to 0.65 between
block 1 and 2, 0.55 between block 2 and 3 and 0.27 be-
tween block 3 and 4. HaploView predicted 51 possible
connections of haplotypes for recombination between
blocks higher than 1 %. However, recombination between
blocks higher than 10 % occurred only between the most
frequent haplotype from block 1 and the most frequent
one from block 2, between three most frequent haplo-
types from block 2 and the most frequent one from
block 3, and between the most frequent one from block
3 and three haplotypes from block 4. Apart from
c.1684 T > C (p.Leu562=), the remaining SNPs in blocks
were tagged in silico as haplotype tag SNPs (htSNPs).
Discussion
In this paper we highlighted the fact that the High Reso-
lution Melting method is a powerful technique both for
targeted genotyping of selected SNPs and for scanning of
long parts of gene sequences. The obtained results for tar-
geted genotyping and scanning of ABCC1 gene regions
did not show statistically significant differences in MAFs
values for most SNPs. Marginal statistical significance
(0.05 > P > 0.01) of difference between MAF values for
scanning and targeted genotyping methods for two SNPs
c.1062 T > C (p.Asn354=) and c.2012G > T (p.Gly671Val)is probably caused by sample size effect (there was no
overlap between groups of individuals selected for both
stages of the study). Seven SNPs from a subset of 17 indi-
vidually genotyped ones were not detected during the
scanning and did not show any genetic variation during
genotyping either. Although these variants were previ-
ously indicated to may have clinical significance and were
therefore included in our study, they were only identified
during in vitro studies or in non Caucasian populations
(Exome Aggregation Consortium (ExAC), Cambridge,
MA (http://exac.broadinstitute.org), date accessed: Aug
2015). Thus, it was expected not to find them in our study
for 380 genotyped samples, where technical or methodo-
logical problems with detection should not have caused
any discrepancy.
During the scanning study we identified 46 polymorphic
variants by screening 30 exons of the ABCC1 gene with
adjacent intronic fragments in 190 unrelated Polish indi-
viduals. A large fraction of variants represented rare or
even completely novel (not previously published) ones.
We were unable to compare them with the ones from the
only other publication on ABCC1 variant distribution in
Caucasians because of unavailability of the raw data from
that study [15].
Comparing our genetic variation results obtained using
the scanning method with data for Asian populations, 18
variants were detected in the Polish population which
were present also in the Japanese one (n = 153) [13], while
13 variants from the Polish population were also detected
in the Chinese one (n = 27) [14]. Some of these variants
exhibited significant differences in MAF values, confirmed
by chi-square test for alleles (with Yates’ correction if any
allele quantity was below 5) and showed as their P-values,
assumed significant if <0.05. Higher MAF for the Polish
population was detected for variant c.809 + 54C >A
(MAF = 0.231, compared to 0.059 for Japanese (P < 0.001)
and 0.093 for Chinese (P = 0.020) populations), synonym-
ous SNP c.4002G > A (MAF = 0.277, compared to 0.196
for Japanese (P = 0.014) and only 0.111 for Chinese (P =
0.009) populations) and for variant c.4126-45G > A be-
tween Polish (MAF = 0.447) and Japanese (MAF = 0.304)
populations (P < 0.001). On the other hand, lower MAF
for Polish population was noticed for variants: c.809 +
64C >A (0.313 for Polish, compared 0.418 (P = 0.004) for
Japanese and 0.481 (P = 0.014) for Chinese populations),
c.1678-37G > A and synonymous SNP c.1684 T > C (for
both SNPs, MAF = 0.130 for Polish, 0.245 (P < 0.001)
for Japanese but not significant for Chinese 0.204 (P =
0.141)), non-synonymous SNP c.2168G > A and dele-
tion variant c.2461-39_2461-38delAT (for both variants,
MAF = 0.024 for Polish, 0.065 (P = 0.007) for Japanese
and not significant for Chinese 0.065 (P = 0.108)),
c.2461-30C > G (for Polish MAF = 0.117, not significant
for Chinese 0.167 (P = 0.299) but for Japanese 0.245











































Haplotypesc C C 0.686 0.65 T T A 0.659 0.45 A C 0.870 0.27 A G 0.447
A G 0.231 C C G 0.300 G T 0.130 G G 0.405
C G 0.082 T C G 0.021 G A 0.148
others 0.001 T C A 0.011
others 0.009
aPosition according to reference sequences for coding nucleotides NM_004996.3 and amino acid residues NP_004987.2. bBold variants signify haplotype tag SNPs (htSNPs). cMajor alleles in white boxes, minor alleles in













Słomka et al. BMC Genetics  (2015) 16:114 Page 14 of 16(P < 0.001)) and c.4487 + 18G >A between Polish (MAF =
0.148) and Japanese (MAF = 0.291, P < 0.001) populations.
These results suggest that although a wide group of com-
mon variants for different populations have had similar
MAF, there are also other polymorphisms which MAF
values were significantly different. Since differences be-
tween Asian populations were consistently smaller than
between them and the Polish population, we can conclude
that ethnic ancestry is probable underlying cause of these
variations. Similar conclusions were described previously
during research of four polymorphisms in ABCC1
gene in Caucasians: c.816G >A, c.825 T > C, c.1684 T > C,
c.4002G >A [32]. All these results correspond to those ob-
tained by Wang et al. [16] who studied 60 SNPs and 10
deletion variants for four populations. During our ABCC1
scanning, we detected 25 common variants and obtained
similar results for Polish population as those authors for
Caucasian representatives. A slight difference in MAF was
observed for few polymorphisms: the highest were seen
for c.809 + 64C > G (MAF = 0.313 for Polish and 0.200
(P = 0.043) for Caucasians) and for c.825 T >C (p.Val275=)
(MAF = 0.309 for Polish population and 0.139 (P = 0.003)
for Caucasians), while the difference for c.4002G >A
(MAF = 0.277 and 0.375 (P = 0.093) for Polish and
Caucasians, respectively) was not significant. Further-
more, their results confirmed our previous observations
concerning ethnic differences in occurrence of the same
polymorphic variants between Caucasian and Asian
populations. These differences relate mainly to the SNPs
mentioned previously as most ethnically significant:
c.809 + 54C > A, c.809 + 64C > A, c.3079 + 62 T > C,
c.4002G > A and c.4126-45G > A.
We performed analysis of linkage disequilibrium
(which is defined as non-random allelic association of
different loci) to summarize our results for those 44
polymorphisms which were found to be consistent with
the Hardy-Weinberg model. It turned out that, as ex-
pected, the r2 coefficient was most useful for analysis,
and we detected polymorphic variant pairs with strong
LD: our results are very similar even to those obtained
for Japanese population [13]. It can be concluded on this
basis that the specific linkages between particular vari-
ants are highly evolutionary conserved and occur in
every population. Human genome is organized in haplo-
type blocks with high LD inside them, separated one
from another by regions of low LD. Blocks show no evi-
dence of historical recombination inside. This definition
of haplotype blocks could be applied to 17 SNPs which
had MAF higher than 0.05, which was the lower thresh-
old in this analysis. We found four blocks and 12 com-
mon haplotypes including nine SNPs detected during
this study. We determined htSNPs which should be suf-
ficient to identify common haplotypes in population.
Low haplotype diversity of ABCC1 in Polish populationis consistent with the conclusion of another study on
Caucasians [15]. Although blocks for our results are
small and the number of SNPs used for haplotype con-
struction is low, the main core of blocks and their bor-
ders are retained across populations regardless of the
blocks definitions used. Our blocks 1 and 2, usually con-
nected as one in other studies, extend from intron 7 to
intron 9. Our block 3 include SNPs from vicinity of exon
13 and block 4 contains SNPs from intron 28 to intron
30. It corresponds to block borders detected in other
studies and suggest points of recombination which had
taken place in intron 12 and in intron 27 or 28 [13–15].
Analysis using PolyPhen-2 which predicts the influ-
ence of detected non-synonymous SNPs on protein
functionality suggested that six of them are suspect.
However, each analysis is only a statistical calculation
based on a full dataset and some experimental data do
not support these results. Létourneau et al. [33] exam-
ined 10 missense SNPs of ABCC1 and almost all of
them, classified by PolyPhen-2 software as deleterious,
affected neither expression nor functionality of the pro-
tein. A similar observation was also reported previously
for the SNP c.2012G > T (p.Gly671Val), detected also by
us. Although this substitution affects a residue near the
highly conserved motif Walker A, it reduced mRNA ex-
pression but did not change transport properties of the
protein, although PolyPhen-2 analysis clearly showed its
damaging impact [34]. Recently, other data confirmed
these observations and none of the amino acid substitu-
tions: p.Arg633Gln, p.Gly671Val, p.Arg723Gln, detected
also in our study, was found to change functionality of
MRP1 transporter. Two substitutions altered drug re-
sistance and inhibitor sensitivity and we found one of
them, c.4002G > A (p.Ser1334=) [35].
On the other hand, there are other papers showing con-
trasting data for above-mentioned variants, proving their
clinical association or experimental impact on protein
functionality. Thus, it was demonstrated that variant
c.2168G >A (p.Arg723Gln) reduced resistance activity of
MRP1-overexpressing cells to drugs like daunorubicin,
doxorubicin, etoposide, vinblastine and vincristine in vitro
[36]. Although correlation between carrying this SNP and
chemotherapy response was not observed in lung cancer
patients [37], this variant was linked to the response to
chemotherapy in patients with ovarian cancer [19]. Two
other polymorphic variants detected in this study
c.825 T > C (p.Val275=) and c.2012G > T (p.Gly671Val),
were correlated with febrile neutropenia as an effect of
FEC-induced hematological toxicity in breast cancer
patients [38]. The major allele variant c.825 T > C
(p.Val275=), in combination with another one c.*543C > T
(beyond our scanning), was also associated with
anthracycline-induced cardiotoxicity after chemotherapy
in children with acute lymphoblastic leukemia [39]. The
Słomka et al. BMC Genetics  (2015) 16:114 Page 15 of 16discrepancy observed in different studies on clinical sig-
nificance of c.2012G > T (p.Gly671Val) and c.2168G >A
(p.Arg723Gln) is of unclear origin. Cellular conditions
in vitro in which mutants were expressed could be inad-
equate to reveal all their real functions, e.g. a change in
mRNA structure could be more essential than the amino
acid change caused by SNP [34]. Conseil and Cole [35]
concluded from this discordance that comprehensive bio-
chemical and pharmacological characterization of the re-
spective MRP1 mutants should be performed to identify
consequences of ABCC1 SNPs on phenotype because
these effects might be quite selective. Additional nucleic
acid-based methods should be also used to clarify the im-
pact of individual SNPs.
These examples show that only comprehensive examin-
ation of polymorphisms and studying their phenotypes can
tell more about their real influence. Therefore, novel vari-
ants like c.596C > T (p.Ser199Leu), detected in this study
and qualified in silico as damaging, need to be checked in
an experimental investigation. Additionally, the fact that
we found no novel mutation in important nucleotide bind-
ing motifs, nor any of the mutations identified previously
in vitro as deleterious in NBD loops, proved that these
highly conserved regions in the protein structure are un-
likely to be affected by polymorphisms occurring in the
healthy population.
Conclusions
We scanned 30 exons and short flanking intron se-
quences of ABCC1. HRM is an efficient and sensitive
method for scanning and genotyping polymorphic vari-
ants. We compared results of long-range scanning to
targeted genotyping of selected SNPs showing that both
methods are highly sensitive tools to study genetic vari-
ation. During our study we found 45 polymorphic vari-
ants, some of them rare and eight of them novel not
previously reported. This is the first study about ABCC1
genetic variation in the Polish population and we found
some ethnic differences in frequency of genetic variants
compared to other populations. These results need fur-
ther complementation with a larger number of probands
and new data including also introns and untranslated
regions as sequences with polymorphic variants which
may have clinical relevance as well.
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